Kolexia
Mahon Francois-Xavier Hématologie
Mahon Francois-Xavier
Hématologie
Institut Bergonié
Bordeaux, France
349 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémie myéloïde chronique BCR-ABL positive Leucémies Leucémie myéloïde Leucémie myéloïde en phase chronique Chromosome Philadelphie Récidive tumorale locale Maladie résiduelle Crise blastique Leucémie-lymphome lymphoblastique à précurseurs B et T

Collaborateurs

Voir plus
Nicolini Franck
Nicolini Franck
Centre Léon-Bérard, Lyon, France
Rea Delphine
Rea Delphine
Hôpital Saint-Louis, Paris, France
Etienne Gabriel
Etienne Gabriel
Institut Bergonié, Bordeaux, France
Rousselot Philippe
Rousselot Philippe
Hôpital Saint-Louis, Paris, France

Industries

Voir plus
Novartis
2 collaboration(s)
Dernière en 2021
Incyte
1 collaboration(s)
Dernière en 2022
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL: A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Essai Clinique (Novartis)   14 mars 2024
ENESTop: A Phase II, Single Arm, Open Label Study of Treatment-free Remission in Chronic Myeloid Leukemia (CML) Chronic Phase (CP) Patients After Achieving Sustained MR4.5 on Nilotinib
Essai Clinique (Novartis)   27 février 2024
Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients.
British journal of haematology   07 février 2024
How to interpret the EURO-SKI study and its treatment-free remission outcome. Reply to R.P. Gale and J. Chen.
Leukemia   03 janvier 2024
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib.
Leukemia   21 décembre 2023
Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
ASC4START and ASC4FIRST: Two Ongoing Phase 3 Trials Investigating Asciminib Monotherapy As First-Line Therapy Versus Tyrosine Kinase Inhibitors in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
65th ASH Annual Meeting Abstracts   02 novembre 2023
Cancer : l'Institut Bergonié à la pointe - France 3 Aquitaine
Youtube @ Institut Bergonié   23 octobre 2023
POSTER: CML-590 ASC4START: A Phase 3b, Open-Label, Randomized Study of Asciminib vs Nilotinib in Patients With Newly Diagnosed Ph+ Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Proceedings of the Society of Hematologic Oncology 2023 Annual Meeting   01 septembre 2023
CML-590 ASC4START: A Phase 3b, Open-Label, Randomized Study of Asciminib vs Nilotinib in Patients With Newly Diagnosed Ph+ Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Proceedings of the Society of Hematologic Oncology 2023 Annual Meeting   01 septembre 2023